Karen Keating

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris, Manish R. Patel, Daniel C. Cho et al. · Journal of Clinical Oncology · 2019 · 144 citations

Life Sciences, Immunology, Oncology +17

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

Jörge E. Cortes, Kenji Tamura, Daniel J. DeAngelo et al. · British Journal of Cancer · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacology +13

Validation of a patient‐administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire

Darren Clayson, D Wild, Helen Doll et al. · British Journal of Urology · 2005 · 113 citations

Medicine, Infectious Diseases, Urology +13

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

Julie E. Bauman, Howard A. Burris, Jeffrey Clarke et al. · 2020 · 54 citations · Full text

Life Sciences, Immunology, Oncology +17

Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital

Karen Keating, Christine M. Walko, Briana Stephenson et al. · Journal of Oncology Pharmacy Practice · 2013 · 47 citations

Life Sciences, Oncology, Allergy +12